Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Op...
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months
LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the ...
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.